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Summary The presence of a patent foramen ovale has been found to be associated with
an increased risk of ischemic stroke of otherwise unknown origin (cryptogenic stroke). The
present article will review the evidence regarding this association, the technical aspects of
PFO detection, and the preventive options to decrease the risk of recurrent cerebral events.
© 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.Echocardiography,
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he foramen ovale is a normal component of the fetal
irculation that usually closes after birth because of the
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Figure 1 Example of patent foramen ovale detection
Figure 2 Detection of microbubbles by transcranial Doppler
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fore resulting in a more accurate distinction between PFO
and intrapulmonary shunt than possible by TTE or TCD.
Major complications resulting from the performance of
TEE are rare (0.2% in a published series) [17].by transthoracic echocardiography with contrast injection.
Microbubbles are visualized ﬁlling the right-sided chambers and
into the left atrium (LA) and left ventricle (LV).
fusion between the two embryologic components of the
atrial septum, the septum primum, and septum secundum.
In many individuals, a small communication persists into
adult life, and is referred to as a patent foramen ovale
(PFO). The frequency of a PFO in the population has been
reported at 15—35% in autopsy studies [1—3] and appears
to decrease with age [3]. In vivo studies that have used
transesophageal echocardiography (TEE) have reported a
prevalence of PFO in the population very similar to that
of the autopsy studies (24.3%) [4]. The prevalence of PFO
has been described as similar across different race-ethnic
groups [5].
Detection of PFO
In its most common variety, a PFO is a virtual conduit located
at the site of conﬂuence of the septum primum and septum
secundum, which opens whenever the pressure in the right
atrium exceeds the pressure in the left atrium. Therefore,
the diagnostic techniques for PFO detection are based on the
direct visualization of the opening or of its functional con-
sequence, the right-to-left shunt. The assessment is usually
performed at rest and during maneuvers, such as the Val-
salva maneuver or cough, which increase the pressure in the
right-sided chambers of the heart and may therefore unmask
a shunt not visible under resting conditions. The diagnos-
tic techniques most commonly used for PFO detection are
TEE, transthoracic echocardiography (TTE), and transcra-
nial Doppler (TCD), performed with contrast injection to
allow the visualization of any right-to-left shunt. The con-
trast material may be aerated and agitated saline solution
or a polygelatine agent. For screening purposes, TTE or TCD
are generally used. TEE is the gold standard for the diag-
nosis due to its higher diagnostic accuracy, but, due to its
semi-invasive nature, is usually reserved to cases in which
a better anatomic deﬁnition of the PFO is needed. With
contrast TTE, the study is considered positive when any
microbubble is seen in the left-sided chamber within three
cardiac cycles after the contrast material ﬁlls the right-
sided chambers (Fig. 1). Contrast TTE has been shown to
have lower sensitivity for PFO detection than TEE (50—60%)
[6—9]. Recent advances in imaging techniques have led to an
F
t
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an the middle cerebral artery of a patient with a patent foramen
vale. Microbubbles are visualized as spikes superimposed on
he normal blood ﬂow.
mproved sensitivity of TTE (80—90%) [10,11]. Probably due
o the lower sensitivity of TTE for small shunts, the preva-
ence of PFO by contrast TTE in the general population has
een reported to be lower than by TEE (14.9% vs. 24.3%)
4,12].
Contrast TCD is also used to detect a PFO (Fig. 2). The
ensitivity of TCD has been shown to be slightly lower than
hat of TEE in some studies [7,13], but essentially equivalent
o it in others [14,15].
TEE is considered the gold standard for the diagnosis of
FO. Its sensitivity and speciﬁcity have been reported to be
ssentially 100% [16]. TEE also allows the direct visualization
f the PFO opening in most patients (Fig. 3), and therefore
he direct measurement of the separation between septum
rimum and secundum as an indicator of PFO size. Also, TEE
llows the direct visualization of the pulmonary veins, there-igure 3 Direct visualization of patent foramen ovale by
ransesophageal echocardiography. A separation (arrow) is seen
etween septum primum and septum secundum. LA, left
trium; RA, right atrium.
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Sigure 4 Visualization of atrial septal aneurysm by trans-
sophageal echocardiography. Protrusion of the atrial septum
owards the right atrium is visible (arrow). LA, left atrium; RA,
ight atrium.
trial septal aneurysm
n atrial septal aneurysm (ASA) is a protrusion of a segment
f atrial septum into either atrial chamber. A protrusion
f at least 10mm with base of at least 10mm is gener-
lly considered diagnostic of ASA [5,18]. The prevalence
f ASA in the population appears to be low (approximately
—4%) [4,12,19]. When present, an ASA is associated with
PFO in over 60% of cases [18,20,21]. TEE can identify
he presence of an ASA very accurately (Fig. 4). TTE can
lso detect an ASA, although with lower sensitivity than TEE
18,20].
FO, ASA, and stroke risk
n the past 20 years, the association between PFO and cryp-
ogenic strokes, which represent up to 40% of ischemic
trokes [22], has been established. The present section will
eview the evidence supporting this association.
ase—control studies
he relationship between PFO and cryptogenic stroke was
rst described in patients younger than 55 [23] or 40 [24]
ears of age. The hypothesized stroke mechanism is para-
oxical embolization, or the embolization to the systemic
rterial circulation of thrombus originated in the venous
irculation. Paradoxical embolization, whose occurrence is
ocumented by the occasional detection of thrombus lodged
n the PFO (Fig. 5), often remains a presumptive rather than
certain diagnosis.
The association between PFO and cryptogenic stroke in
ounger patients was conﬁrmed in multiple studies with
TE or TEE [25—29]. Overall, younger stroke patients have
4-fold increase in PFO prevalence compared to stroke-
ree control subjects of the same sex and age (Table 1A).
he association has been more controversial in elderly
ubjects, in whom it has been invoked [27] or negated
30,31]. Recently, a TEE study reafﬁrmed its existence in
T
t
p
aigure 5 Visualization by transesophageal echocardiography
f large thrombus crossing the patent foramen ovale (arrows).
A, left atrium; RA, right atrium.
he older age group after adjustment for other stroke risk
actors (odds ratio 3.00, 95% conﬁdence interval 1.73—5.23;
< 0.001) [29]. The strength of the association was in fact
imilar to that observed in younger patients (odds ratio
.70, 95% conﬁdence interval 1.42—9.65; p = 0.008) [29].
ombined results from studies in the elderly suggest the
xistence a 2-fold increase in PFO prevalence in stroke
atients compared to controls (Table 1B). Therefore, the
ssociation between PFO and cryptogenic stroke appears
o exist in all age groups, although it may be stronger in
ounger individuals.
ASA has also been linked to an increased risk of ischemic
troke. ASA was signiﬁcantly more frequent in patients with
ryptogenic stroke than in controls (15% vs. 4%; p < 0.05)
20]. However, a coexisting PFO is very often seen in patients
ith ASA (60—70% of cases), and the PFO size tends to be
arger in them [21,32]. Therefore, the associated stroke risk
ay reﬂect the frequent coexistence of a PFO. However,
he coexistence of the two abnormalities may be a stronger
troke risk factor than either condition alone. In a meta-
nalysis, the odds ratio for stroke was 1.83 for PFO alone
nd 2.35 for ASA alone, but 4.96 for their combination [31].
n stroke patients below age 55 treated with aspirin, the
-year recurrent stroke rate was markedly higher (15.2%) in
hose with combined PFO and ASA than in those with isolated
FO (2.3%) or no PFO (4.2%) [33]. Patients with PFO and ASA
ere shown to have more often multiple acute brain lesions,
hallmark of embolic mechanism, than patients with PFO
lone (53% vs. 17%; p = 0.01) [34]. Other potential stroke
echanisms from an ASA include in situ thrombus formation,
hich is probably rare [18]; a predisposition to the devel-
pment of atrial arrhythmias, which remains controversial
35,36]; and left atrial dysfunction, a precursor of thrombus
ormation [37].
troke risk in the general populationhe above data were obtained from case—control studies,
herefore on individuals that had already had an event com-
ared to stroke-free-subjects of similar sex and age. This
pproach, although effective, suffers from an inherent risk
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Table 1A Relationship of cryptogenic stroke with PFO in younger patients.
Study Patients PFO (cryptogenic) PFO (control) p-Value
N Age
Lechat [23] 26 <55 54% (14/26) 10% (10/100) <0.001
Webster [24] 34 <40 56% (19/34) 15% (6/40) <0.001
Cabanes [25] 64 <55 56% (36/64) 18% (9/50) <0.001
de Belder [26]a 39 <55 13% (5/39) 3% (1/39) —
Di Tullio [27] 21 <55 47% (10/21) 4% (1/24)b <0.001
Hausmann [28] 18 <40 50% (9/18) 11% (2/18) <0.05
Handke [29] 82 <55 44% (36/82) 14% (7/49)b <0.001
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ASA [21], and unexplained arterial embolism [42].Total 45%
a Includes different stroke subtypes.
b Controls were patients with stroke of known cause.
of incomplete matching of cases and controls with regard
to pertinent variables, and may therefore lead to biased
results. Prospective studies do not suffer from those limi-
tations, and two such studies examined the role of a PFO
in the general population. In the Stroke Prevention: Assess-
ment of Risk in a Community (SPARC) study, the stroke risk
from cardiac embolic sources was investigated by TEE [4].
The prevalence of PFO was 24.3%. Over a median follow-
up of approximately 5 years, PFO was found not to be
independently associated with increased risk of cerebrovas-
cular events (hazard ratio 1.46, 95% conﬁdence interval
0.74—2.88). In the population-based Northern Manhattan
Study (NOMAS), the presence of a PFOwas sought by contrast
TTE in 1100 stroke-free individuals [12]. PFO prevalence
was lower (14.9%), reﬂecting the lower sensitivity of TTE.
Over a mean follow-up of almost 7 years, PFO was not
independently associated with ischemic stroke (hazard ratio
1.64, 95% conﬁdence interval 0.87—3.09). Therefore, the
two studies, although on different populations and using dif-
ferent diagnostic tests, obtained remarkably similar results,
with a slight, non-signiﬁcant increase in stroke risk in indi-
viduals with PFO. Both studies hinted at an increased stroke
risk from an ASA, but numbers were too small to allow any
conclusions. The presence of both PFO and ASA did not
increase the stroke risk in NOMAS, while the information
was not available in SPARC. In general, these studies did
not support the concept of an increased stroke risk from a
PFO, although the possibility exists that a signiﬁcant effect
might have been observed with larger sample sizes or longer
follow-up durations.
H
C
t
Table 1B Relationship of cryptogenic stroke with PFO in older pa
Study Patients PFO (cryptogen
N Age
de Belder [26]a 64 >55 20% (1
Di Tullio [27] 24 >55 38% (9
Hausmann [28] 20 >40 15% (3
Jones [30] 57 >50 18% (1
Handke [29] 145 >55 28% (4
Total 25% (7
a Includes different stroke subtypes.
b Controls were patients with stroke of known cause.29/284) 11% (36/320) <0.001
ossible associated factors
ince the results of the population-based prospective stud-
es did not conﬁrm the result of the case—control studies, it
ppears that co-factors may exist that increase the risk asso-
iated with a PFO, and may be more frequently present in
troke patients. This section will review some of the poten-
ial co-factors.
natomical variants
he size of the PFO (intended as the separation between sep-
um primum and septum secundum on TEE) has been linked
ith stroke risk in multiple studies [38,39].
The degree of shunt through the PFO (inferred from the
ount of microbubbles in the left atrium) has also been asso-
iated with stroke risk, although this has not been conﬁrmed
n recent studies [40].
The role of a prominent Eustachian valve (the remnant
f the valve that directs the blood from the inferior vena
ava to the fossa ovalis of the atrial septum) as a co-factor
n the stroke risk has been controversial [39,41]. An exam-
le of thrombus on Eustachian valve is presented in Fig. 6.
Chiari’s network (a web-like network of threads and ﬁbers
ariably connecting the Eustachian valve to other atrial
tructures) is more frequently seen in patients with a PFO,emodynamic factors
onditions that increase the right atrial pressure have
he potential to increase the degree of right-to-left shunt
tients.
ic) PFO (control) p-Value
3/64) 5% (3/56) <0.001
/24) 8% (6/77)b <0.001
/20) 23% (23/98) NS
0/57) 16% (29/183) NS
1/145) 12% (28/232)b <0.001
6/310) 14% (89/646) <0.001
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tigure 6 Visualization by transesophageal echocardiography
f large thrombus (arrow) on the Eustachian valve. LA, left
trium; RA, right atrium; SVC, superior vena cava.
hrough the PFO, and therefore the likelihood of paradox-
cal embolization. Pulmonary embolism, right ventricular
nfarction, and severe tricuspid regurgitation have been
ssociated with increased shunting through a PFO.
eep venous thrombosis (DVT)
he presence of a DVT can enhance the risk of paradoxical
mbolization through a PFO. An increased prevalence of DVT
n cryptogenic stroke patients with a PFO was reported [43],
ut not conﬁrmed [44]. The diagnostic technique used is also
mportant, as pelvic vein thrombi, a potential source for
aradoxical embolism [45], may be diagnosed by venography
r MRI venogram, but are difﬁcult to assess by ultrasound
echniques.
rothrombotic states
lood hypercoagulability may facilitate thrombus forma-
ion in the vascular system, providing the substrate for
aradoxical embolization. G20210A and factor V Leiden
utations have been reported in patients with cryptogenic
troke and PFO [46,47]. One of these prothrombotic geno-
ypes, more often G20210A mutation, was more frequently
bserved in young cryptogenic stroke patients than in age-
atched controls (10.3% vs. 2.5%; p = 0.008), and increased
he stroke risk by over 4-fold [48]. The combination of
FO and antiphospholipid antibodies did not signiﬁcantly
ncrease the stroke risk stroke in a multicenter study [49].
ecent surgery, trauma, or use of oral contraceptives may
e associated with blood hypercoagulability and consequent
reater potential for paradoxical embolization [50].
revention of recurrent events
he efforts to prevent recurrent events have focused on
ecreasing the likelihood of thrombosis or closing the PFO.
ntithrombotic treatment
he most frequently used antithrombotic drugs have been
itamin K inhibitors (such as warfarin) and antiplatelet
gents, especially aspirin. From various meta-analyses, the
ate of recurrent stroke or transient ischemic attack (TIA)
hile on these treatments was 4 events/100 person-years
51], and almost 5 events/100 person-years when death
c
o
d
w
gS. Homma, M.R. Di Tullio
as also included [52]. In most studies, the treatment was
ot randomized. The only trial with randomized treatment
ssignment was the Patent Foramen Ovale in Cryptogenic
troke study (PICSS), a TEE-based substudy of the Warfarin
spirin Recurrent Stroke Study (WARSS), which randomized
atients with non-cardioembolic stroke to aspirin 325mg
r warfarin (target international normalized ratio 1.4 to
.8) [53]. In PICSS, 630 patients underwent TEE early after
troke. Over 2 years of follow-up, no signiﬁcant differ-
nces in rates of recurrent stroke and death were observed
etween patients with and without a PFO (hazard ratio
.96, 95% conﬁdence interval 0.62—1.48), even in patients
ith cryptogenic stroke (hazard ratio 1.17, 95% conﬁdence
nterval 0.60—2.37) [54]. Similar results had been previously
btained in two studies in which the treatment was either
ot randomized (La Sapienza study, 86 cryptogenic stroke
atients treated with aspirin, warfarin, both or neither)
55] or consisted of only aspirin (PFO/ASA French study, 581
troke patients below age 55) [33]. No signiﬁcant differences
n annual rates of stroke or death were reported between
troke patients with and without a PFO (3.7% vs. 4.5% in
a Sapienza study; 1.5% vs. 1.8% in the PFO/ASA French
tudy). The French study documented a higher annual event
ate (3.7%) for patients with both PFO and ASA, raising the
uestion that aspirin may not be sufﬁcient protection in
hose patients. In PICSS, however, the combination of PFO
nd ASA did not carry an increased risk of recurrent events
ompared with neither condition (hazard ratio 1.04, 95%
onﬁdence interval 0.51—2.12). This ﬁnding was conﬁrmed
y the Spanish Right-to-Left Shunt in Cryptogenic Stroke
CODICIA) study on 200 stroke patients with PFO treated with
arfarin or aspirin [40]. The presence of larger shunt was
lso not found to signiﬁcantly affect the risk of recurrent
vents in PICSS [54] or CODICIA [40].
It therefore appears that antithrombotic treatment
educes the risk of recurrent events in stroke patients with a
FO to the level of stroke patients without it. By combining
he data of PICSS, La Sapienza, and PFO/ASA studies, the
azard ratio of PFO for recurrent stroke and death is 0.95
56]. While conclusive data are not available on the relative
fﬁcacy of warfarin and aspirin treatment, the event rates
bserved in PICSS did not suggest a deﬁnite advantage for
ither treatment.
FO closure
urgery. Surgical PFO closure was initially performed in
elected cryptogenic stroke patients, and has become
nfrequent since the introduction of percutaneous clo-
ure devices. A low incidence of recurrent cerebrovascular
vents was reported after surgical closure in younger
atients [57,58], but not in older ones [57]. A meta-analysis
n 161 patients (mean age 43 years) reported an annual
isk of recurrent stroke or death of 0.85% (95% conﬁdence
nterval, 0.10—3.07%) [52].
PFO closure is sometimes performed prophylactically in
atients undergoing open heart surgery for other indica-
ions, but this practice is questioned. A study on over 13,000
ardiac operations showed no signiﬁcant differences in peri-
perative stroke (2.3% vs. 2.3%; p = 0.84) and in-hospital
eath (3.4% vs. 2.6%; p = 0.11) between patients with or
ithout a PFO; however, patients who had their PFO sur-
ically closed experienced a 2.5-fold increase in the risk of
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RFigure 7 Visualization by transthoracic echocardiography
(long-axis view) of a patent foramen ovale closing device. RV,
right ventricle; RA, right atrium.
in-hospital stroke compared with those who did not (2.8%
vs. 1.2%; p = 0.04), and showed no long-term survival beneﬁt
over a mean follow-up of 5.6 years [59].
Transcatheter closure. The introduction of percutaneous
closure devices has offered a less invasive alternative for
closing a PFO. An example of PFO closure is shown in
Fig. 7. Data on the efﬁcacy of these devices have come
from case series and non-randomized studies. In a pooled
analysis of studies published until 2004 [52], the combined
rate of recurrent stroke, death, or TIA for PFO closure
was 2.95 events/100 person-years. As devices have been
improved, the incidence of recurrent events has decreased.
In 131 patients, no recurrent embolic events were reported
over a mean follow-up of 30 months [60]. Complications
from device implantation have also decreased. In a meta-
analysis of 1355 patients, major complications such as
death, major hemorrhage, cardiac tamponade, and fatal
pulmonary emboli were reported in approximately 1.5%
[61]. Other complications such as atrial arrhythmias, device
arm fractures, embolization or thrombosis, EKG changes,
and arterio-venous ﬁstula formation were observed in 7.9%
[61]. In a multicenter European study on 430 patients, peri-
procedural complications occurred in 11.5% of patients, 0.2%
of which deﬁned as major [62].
Transcatheter PFO closure may cause microembolization
to the brain. Transient microembolic signals were detected
by TCD in 28 of 29 patients during the procedure [63]. Repeat
brain MRI documented new microembolic lesions after PFO
closure in 3 of 35 subjects (8.6%) [64].
Atrial ﬁbrillation is relatively frequent after PFO closure,
with an annual incidence of 2.5%, which appears not related
to device type or size [65].
Antithrombotic treatment vs. PFO closure
Several randomized trials comparing PFO closure and
antithrombotic treatment are ongoing, but the ﬁrst results
are not expected until at least 2011 [66]. So far, the patient
populations in studies that have looked at PFO closure
and studies that have examined antithrombotic treatment
have differed. In general, patients in PFO closure studies
tended to be younger and have higher frequency of previous
thromboembolic events, whereas patients in the medical
treatment studies tended to have higher frequencies of139
raditional stroke risk factors such as diabetes and cigarette
moking [61]. In 308 cryptogenic stroke patients with
FO treated medically (158 patients) or with PFO closure
150 patients), recurrent stroke or TIA tended to be less
requent in the closure group (7.8% vs. 22.2%; p = 0.08;
5% conﬁdence interval 0.23—1.11), especially in patients
ith multiple cerebrovascular events at baseline [67]. As
reatment was not randomized, patients with larger PFOs
r multiple cerebrovascular events were more frequently
ssigned to PFO closure.
Because of the lack of data from randomized clinical
rials, the treatment choice has been empirical. Support-
rs of PFO closure deem the available data strong enough
ot to withhold a potentially life-saving treatment while
waiting the results of randomized clinical trials [68]. Sup-
orters of medical treatment argue that such treatment has
een proven to essentially eliminate the PFO-related risk of
troke, and that a therapeutic paradigm shift such as PFO
losure in stroke patients should only be entertained after
vidence of its superiority has been proven by randomized
rials [69]. The 2006 American Heart Association/American
troke Association guidelines for the prevention of stroke in
atients with ischemic stroke or TIA deemed the available
vidence insufﬁcient to recommend PFO closure in patients
ith a ﬁrst stroke [70]. Aspirin treatment was considered
dequate in most stroke patients, with warfarin treatment
ecommended instead in case of coexisting DVT or prothrom-
otic state. The guidelines recommended to consider PFO
losure in patients with recurrent cryptogenic stroke despite
edical therapy [70].
onclusion
lthough the association between PFO and increased risk of
troke has been established, the role of a PFO as a stroke
isk factor in the general population has not been conﬁrmed.
o preventive treatment is therefore necessary in individ-
als with an incidentally detected PFO. In stroke patients,
reatment with antiplatelet agents (aspirin) appears to con-
er sufﬁcient protection against recurrent events. Systemic
nticoagulation should be preferred in patients with coex-
sting DVT or prothrombotic conditions. While awaiting the
esults of randomized trials, PFO closure appears indicated
n patients with contraindications to medical treatment,
r who experience recurrent events while on it. Further
esearch is necessary to establish the optimal preventive
reatment in patients with the more infrequent combination
f ASA and PFO. Finally, a better understanding of co-factors
hat may increase the PFO-related stroke risk may allow a
ore rational and targeted approach to preventing recur-
ent embolic events.
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